The interplay between direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C

Abstract

Direct-acting antivirals (DAAs) have been introduced for the treatment of hepatitis C virus, and the sustained virological response rate after DAAs was reported to be over 95%. Because of the high sustained virological response rate, the risk of hepatocellular carcinoma (HCC) was expected to be reduced. However, an unexpected high risk of HCC recurrence after DAA treatment was reported, and thus the dispute about the association of DAA and HCC arose. The present article reviews the interplay between DAAs and HCC.

Keywords

Chronic hepatitis C / hepatocellular carcinoma / direct-acting antivirals

References

[1] Marrero JA,Sirlin CB,Finn RS.Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases..Hepatology2018;68:723-50

[2] Manns MP,Gordon SC,Shiffman M.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial..Lancet2001;358:958-65

[3] Zeuzem S,Bourliere M,Marcellin P.Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3..J Hepatol2004;40:993-9

[4] Lee SD,Cheng PN,Chao YC.Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan..J Viral Hepat2005;12:283-91

[5] Morgan TR,Kim HY,Shiffman ML.Outcome of sustained virological responders with histologically advanced chronic hepatitis C..Hepatology2010;52:833-44 PMCID:PMC2932862

[6] Lok AS,Wright EC,Kim HY.Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C..Gastroenterology2011;140:840-9 PMCID:PMC3057272

[7] van der Meer AJ,Feld JJ,Dufour JF.Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis..JAMA2012;308:2584-93

[8] Kowdley KV,Poordad F,Nelson DR.Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1..N Engl J Med2014;370:222-32

[9] Lawitz E,Pang PS,Ding X.Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial..Lancet2014;383:515-23

[10] Muir AJ,Lalezari J,Dore GJ.Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis..JAMA2015;313:1736-44

[11] Lawitz E,Akarca US,Preotescu LL.Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis..Gastroenterology2015;149:971-80.e1

[12] Kwon JH,Nam SW,Kim CW.Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea..J Med Virol2019;91:1104-11

[13] Reig M,Perello C,Ribeiro A.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy..J Hepatol2016;65:719-26

[14] Conti F,Scuteri A,Bolondi L.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals..J Hepatol2016;65:727-33

[15] Masuzaki R,Yoshida H,Sato S.Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography..J Clin Gastroenterol2008;42:839-43

[16] Goodgame B,Galanko J.The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?.Am J Gastroenterol2003;98:2535-42

[17] Kanwal F,Asch SM,Cao Y.Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents..Gastroenterology2017;153:996-1005.e1

[18] Calvaruso V,Cacciola I,Madonia S.Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents..Gastroenterology2018;155:411-21.e4

[19] Romano A,Piovesan S,Anastassopoulos G.Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study..J Hepatol2018;69:345-52

[20] Nagata H,Asahina Y,Asano Y.Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C..J Hepatol2017;67:933-9

[21] Nahon P,Bourcier V,Marcellin P.Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs..Gastroenterology2018;155:1436-50.e6

[22] Yoo SH,Nam SW,Kim CW.Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: comparison with pegylated interferon-based therapy in chronic hepatitis C patients..J Viral Hepat2018;25:1189-96

[23] Singer AW,Telep LE,Brainard DM.Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study..Aliment Pharmacol Ther2018;47:1278-87

[24] Carrat F,Dorival C,Diallo A.Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study..Lancet2019;393:1453-64

[25] Ide T,Nakano M,Yatsuhashi H.Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study..Hepatol Int2019;13:293-301

[26] Poon RT,Lo CM,Wong J.Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation..Ann Surg2002;235:373-82 PMCID:PMC1422443

[27] Tabrizian P,Shrager B,Roayaie S.Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis..Ann Surg2015;261:947-55

[28] Shen YC,Chen LT,Hu FC.Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach..J Hepatol2010;52:889-94

[29] Ikeda K,Saitoh S,Suzuki Y.Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer..Hepatology2000;32:228-32

[30] Kubo S,Hirohashi K,Shuto T.Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial..Ann Intern Med2001;134:963-7

[31] Lin SM,Hsu CW,Sheen IS.Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors..Cancer2004;100:376-82

[32] Mazzaferro V,Schiavo M,Camerini T.Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis..Hepatology2006;44:1543-54

[33] ANRS collaborative study group on hepatocellular carcinomaLack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts..J Hepatol2016;65:734-40

[34] Cabibbo G,Calvaruso V,Cannavo MR.Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study..Aliment Pharmacol Ther2017;46:688-95

[35] Nishibatake Kinoshita M,Tateishi R,Nakagomi R.Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy..J Hepatol2019;70:78-86

[36] Waziry R,Grebely J,Law M.Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression..J Hepatol2017;67:1204-12

[37] Singal AG,Mehta N,Pillai A.Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study..Gastroenterology2019;156:1683-92.e1 PMCID:PMC6598433

[38] Kanda T,Wei L,Yu ML.APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation..Hepatol Int2019;13:649-61 PMCID:PMC6861433

[39] Dang H,Yasuda S,Iio E.Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West..Hepatology2019;

[40] Cheung MCM,Hudson BE,McLauchlan J.Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis..J Hepatol2016;65:741-7

[41] Hanafy AS,Basha MAA.Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated?.Hepatol Int2019;13:165-72

[42] Ioannou GN,Berry K.HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma..J Hepatol2018;1:25-32